Table 1 Common Platelet-rich Therapy Preparation Systems.
System Volume
Of Blood
(mL)		 Centrifuge
Time/Speed		 Final PRP
Volume
(mL)		 Final Platelet
Concentration
(compared with
average)		 Activator Level of Growth
Factors (compared
with average)
Autologous Conditioned Plasma (Arthrex, Naples, FL)†  9 5 min/1,500 rpm 3-5 2-3x None PDGF (25x)
EGF (5x)
VEGF (11x)
TGF-β1 (4x)
IGF-1 (1x)
Cascade (Musculoskeletal Tissue
Foundation, Edison, NJ)‡		 9 or 18 First: 6 min/1,100g;
Second: 15 min/
1,450g		 2 or 4 N/A Calcium
(forms a
suturable
clot for
intraoperative
use)		 PDGF (N/A)
EGF (5-10x)
VEGF (5-10x)
TGF-β1 (5-10x)
IGF-1 (5-10x)
GPS III (Biomet, Warsaw, IN)§ 27 or 54 15 min/1,900g 3 or 6 4-8x Calcium
chloride/
thrombin		 PDGF (N/A)
EGF (3.9x)
VEGF (6.2x)
TGF-β1 (3.6x)
IGF-1 (1x)
SmartPReP
(Harvest Technologies, Plymouth,
MA)†–		 20 or 60 14 min/1,000g 3 or 7 4.4-7.6x Thrombin PDGF (4.4×)
EGF (4.4×)
VEGF (4.4×)
TGF-β1 (4.4×)
IGF-1 (N/A)
* Information obtained from product manufacturers (platelet and growth factor concentration obtained from unpublished company data for all products listed except for Biomet GPS III [Eppley et al.])†  Arthrex: https://www.arthrex.com/innovations/index.cfm?adid=28&CFID=2168033&CFTOKEN=63754575‡ Musculoskeletal Tissue Foundation: http://platelettherapy.com/§ Biomet: http://www.biomet.com/biologics/information/pdf/BBI0003.0.pdf†– Harvest Technologies: http://www.harvesttech.com/products/smartprepmain.htmlEGF = epidermal growth factor, IGF-1 = insulin-like growth factor-1, N/A = not available, PDGF = platelet-derived growth factorPRP = platelet-rich plasmaTGF-β1 = transforming growth factor-β1VEGF = vascular endothelial growth factor